interferon alfacon-1
Trade name: Infergen
Recombinant proteinapproved
Approved
Oct 6, 1997
Interferon alfacon-1 is a recombinant synthetic type I interferon used for the treatment of hairy cell leukemia, malignant melanoma and AIDS-related Kaposi's sarcoma. — Wikipedia
Clinical trial activity
10 trials · 13 clinical orgs · 1 marketing orgs
Phase 1
1
Phase 2
7
Phase 3
4
Phase 4
2
Earliest trial started Apr 1, 2004 (NCT00084279)
Timeline
Indications
Approved for
Mechanism of action
Interferon alpha/beta receptor agonist
Alpha subunit is binding site
- Interferon alphaSupplementation
Interferon alpha supplementation
- Interferon alpha-17 (IFNA17) ↗
- Interferon alpha-4 (IFNA4) ↗
- Interferon alpha-14 (IFNA14) ↗
- Interferon alpha-6 (IFNA6) ↗
- Interferon alpha-8 (IFNA8) ↗
- Interferon alpha-5 (IFNA5) ↗
- Interferon alpha-10 (IFNA10) ↗
- Interferon alpha-2 (IFNA2) ↗
- Interferon alpha-1/13 (IFNA1; IFNA13) ↗
- Interferon alpha-7 (IFNA7) ↗
- Interferon alpha-21 (IFNA21) ↗
- Interferon alpha-16 (IFNA16) ↗
Approval history
- approvedOct 6, 1997
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Black box warning
Sources
- WikipediaInterferon alfacon-1 ↗
- NCATS56588OP40D ↗
- ChEMBLCHEMBL1201557 ↗
Also known as
- alfacon-1
- cifn
- cifn (interferon)
- consensus ifn-alpha
- consensus interferon
- ifn alfacon-1
- ifn-alpha con 1
- inferax
- infergen
- infergen
- infergen
- infergen
- interferon alfacon-1
- interferon alfacon-1
- interferon alfacon-1
- interferon alfacon-1
- interferon alfacon-1
- interferon alfacon-1
- interferon-alpha con(1)
- interferon consensus, methionyl
- methionyl interferon consensus
- methionyl-interferon-consensus
- rcon-ifn
- recombinant consensus interferon
- recombinant consensus interferon alpha
- recombinant methionyl human consensus interferon
- rifn-con-1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04469491 | Phase 2 | Sep 20, 2020 | University of Picardie Jules Verne |
| NCT04275388 | N/A | Feb 14, 2020 | Qingfeng Pharmaceutical Group |
| NCT01227798 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2010 | University of Toronto |
| NCT00456248 | Phase 4 | Feb 1, 2007 | Kadmon, Virginia Commonwealth University |
| NCT00266318 | Phase 4 | Dec 1, 2005 | Harvard University, Icahn School of Medicine at Mount Sinai, InterMune |
| NCT00239252 | Phase 3 | Sep 13, 2005 | Astellas, Schering-Plough |
| NCT00211692 | Phase 3 | Jul 1, 2005 | Department of Veteran Affairs, InterMune, Kadmon, Minnesota Veterans Medical Research and Education Foundation |
| NCT00162734 | Phase 3 | Feb 1, 2005 | Bausch Health Companies |
| NCT00086541 | Phase 3 | Jun 1, 2004 | Bausch Health Companies |
| NCT00084279 | Phase 2 | Apr 1, 2004 | InterMune |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| InterMune | For profit | 3 | 1 | 3 | 2004 |
| Bausch Health Companies | For profit | 2 | 2 | 1 | 2004 |
| Kadmon | For profit | 2 | 1 | 2 | 2005 |
| Astellas | For profit | 1 | 1 | 1 | 2005 |
| Department of Veteran Affairs | Government | 1 | 1 | 1 | 2005 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2005 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Minnesota Veterans Medical Research and Education Foundation | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Qingfeng Pharmaceutical Group | For profit | 1 | 1 | 1 | 2020 |
| Schering-Plough | For profit | 1 | 0 | 1 | 2005 |
| University of Picardie Jules Verne | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Virginia Commonwealth University | Academic/Hospital | 1 | 0 | 1 | 2007 |
13 organizations
Page 1 / 1